

Amendment to the Claims

This listing of the claims replaces all prior versions and listings of the claims in the application.

Listing of the Claims:

1-66. (Canceled)

67. (Currently Amended) A method of treating an ACE2 decreased state comprising ~~administering to~~identifying an ACE2 decreased state in a mammal having hypertension, congestive heart failure, chronic heart failure, acute heart failure, myocardial infarction, arteriosclerosis, renal failure, and/or lung disease, and administering to the mammal a therapeutically effective amount of an ACE2 polypeptide, wherein the ACE2 decreased state is treated.

68. (Previously Presented) The method of claim 67, wherein the mammal is a human.

69-72. (Canceled)

73. (Currently Amended) The method of claim 67, further comprising administering an ACE inhibitor to the mammal ~~an effective amount of an ACE2 polypeptide, wherein the ACE2 polypeptide is co-administered with an ACE inhibitor.~~

74-99. (Canceled)

100. (Previously Presented) The method of claim 67, wherein the mammal has a lung disease.

101. (Previously Presented) The method of claim 100, wherein the lung disease is acute respiratory distress syndrome.

102. (Previously Presented) The method of claim 100, wherein the lung disease is lung cancer.

103. (Canceled)

104. (Previously Presented) The method of claim 100, wherein the lung disease is chronic obstructive pulmonary disease, pneumonia, asthma, chronic bronchitis, pulmonary emphysema, cystic fibrosis, interstitial lung disease, primary pulmonary hypertension, pulmonary embolism, pulmonary sacrodosis, tuberculosis, or lung edema.
105. (Previously Presented) The method of claim 67, wherein the ACE2 polypeptide is a mouse ACE2 polypeptide.
106. (Previously Presented) The method of claim 67, wherein the ACE2 polypeptide is a rat ACE2 polypeptide.
107. (Previously Presented) The method of claim 67, wherein the ACE2 polypeptide is a human ACE2 polypeptide.
108. (Previously Presented) A method of treating a lung disease comprising administering to a mammal having a lung disease a therapeutically effective amount of an ACE2 polypeptide, wherein the lung disease is treated.
109. (Previously Presented) The method of claim 108, wherein the lung disease is acute respiratory distress syndrome.
110. (Previously Presented) The method of claim 108, wherein the lung disease is pulmonary hypertension.
111. (Previously Presented) The method of claim 108, wherein the lung disease is chronic obstructive pulmonary disease, pneumonia, asthma, chronic bronchitis, pulmonary emphysema, cystic fibrosis, interstitial lung disease, lung cancer, pulmonary embolism, pulmonary sacrodosis, tuberculosis, or lung edema.
112. (Previously Presented) The method of claim 108, wherein the mammal is a human.
113. (Previously Presented) The method of claim 108, wherein the ACE2 polypeptide is a mouse ACE2 polypeptide.

114. (Previously Presented) The method of claim 108, wherein the ACE2 polypeptide is a rat ACE2 polypeptide.
115. (Previously Presented) The method of claim 108, wherein the ACE2 polypeptide is a human ACE2 polypeptide.
116. (Previously Presented) A method of treating a cardiovascular disease comprising administering to a mammal having a cardiovascular disease a therapeutically effective amount of an ACE2 polypeptide, wherein the cardiovascular disease is treated.
117. (Previously Presented) The method of claim 116, wherein the cardiovascular disease is chronic heart failure.
118. (Previously Presented) The method of claim 116, wherein the cardiovascular disease is myocardial infarction.
119. (Previously Presented) The method of claim 116, wherein the cardiovascular disease is hypertension.
120. (Previously Presented) The method of claim 116, wherein the cardiovascular disease is acute heart failure, left ventricular hypertrophy, or cardiomyopathy.
121. (Previously Presented) The method of claim 116, wherein the mammal is a human.
122. (Previously Presented) The method of claim 116, wherein the ACE2 polypeptide is a mouse ACE2 polypeptide.
123. (Previously Presented) The method of claim 116, wherein the ACE2 polypeptide is a rat ACE2 polypeptide.
124. (Previously Presented) The method of claim 116, wherein the ACE2 polypeptide is a human ACE2 polypeptide.
125. (Previously Presented) A method of treating a kidney disease comprising administering to a mammal having a kidney disease a therapeutically effective amount of an ACE2 polypeptide, wherein the kidney disease is treated.

126. (Previously Presented) The method of claim 125, wherein the kidney disease is kidney failure.
127. (Previously Presented) The method of claim 125, wherein the mammal is a human.
128. (Previously Presented) The method of claim 125, wherein the ACE2 polypeptide is a mouse ACE2 polypeptide.
129. (Previously Presented) The method of claim 125, wherein the ACE2 polypeptide is a rat ACE2 polypeptide.
130. (Previously Presented) The method of claim 125, wherein the ACE2 polypeptide is a human ACE2 polypeptide.
131. (New) The method of claim 68, wherein the ACE2 polypeptide is a human ACE2 polypeptide.
132. (New) The method of claim 67, wherein identifying the ACE2 decreased state comprises detecting an ACE2a-ACE2m polymorphism.
133. (New) The method of claim 67, wherein identifying the ACE2 decreased state comprises Northern blot analysis of ACE2 mRNA levels.
134. (New) The method of claim 67, wherein identifying the ACE2 decreased state comprises Western blot analysis of ACE2 protein levels.